Latest On Cyclerion Therapeutics, Inc (CYCN):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-15 22:52 EST | News | Cyclerion announces 1 for 20 reverse stock split | N/A |  |
| 2023-05-12 08:19 EST | News | Cyclerion Therapeutics down 6% on spin off agreement | N/A | |
| 2023-03-27 13:59 EST | News | Cyclerion's zagociguat gets FDA orphan drug status | N/A | |
| 2022-11-22 18:57 EST | News | Cyclerion stock surges 16% on rejecting offer from CEO led group to buy assets | N/A | |
| 2022-10-06 10:24 EST | News | Cyclerion stock tanks 32% on workforce reduction, clinical development refocus | N/A | |
About Cyclerion Therapeutics, Inc (CYCN):
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with prese read more...rved ejection fraction. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
General
- Name Cyclerion Therapeutics, Inc
- Symbol CYCN
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 34
- Fiscal Year EndDecember
- IPO Date2019-04-02
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Web URLhttp://www.cyclerion.com
Valuation
- Price/Sales (Trailing 12 Mt.) 58.53
- Price/Book (Most Recent Quarter) 2.53
- Enterprise Value Revenue 61.79
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.31
- Next Year EPS Estimate -$1.00
- Operating Margin -3420%
- Return on Assets -33%
- Return on Equity -99%
- Revenue 2.3 million
- Earnings Per Share -$4.74
- Revenue Per Share $0.08
- Gross Profit 2.3 million
- Quarterly Earnings Growth -91%
Highlights
- Market Capitalization 143.37 million
- EBITDA -118158000
- PE Ratio -0.74
- Analyst Target Price $4
- Book Value Per Share $1.75
Share Statistics
- Shares Outstanding 33.96 million
- Shares Float 22.68 million
- % Held by Insiders 1505%
- % Held by Institutions 72.16%
- Shares Short 545983
- Shares Short Prior Month 688746
- Short Ratio 0.38
- Short % of Float 2%
- Short % of Shares Outstanding 2%
Technicals
- 52 Week High $8.96
- 52 Week Low $2.18
- 50 Day Moving Average 4.11
- 200 Day Moving Average 4.16
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Cyclerion Therapeutics, Inc (CYCN) Dividend Calendar:
Cyclerion Therapeutics, Inc (CYCN) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Cyclerion Therapeutics, Inc (CYCN) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Cyclerion Therapeutics, Inc (CYCN) Chart:
Cyclerion Therapeutics, Inc (CYCN) News:
Below you will find a list of latest news for Cyclerion Therapeutics, Inc (CYCN) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Cyclerion Therapeutics, Inc (CYCN) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest CYCN Trades:
Cyclerion Therapeutics, Inc (CYCN) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-06 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-11-05 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-10-14 | 8-K (Current report) | |
| 2020-10-01 | 8-K (Current report) | |
| 2020-09-22 | S-8 (Securities to be offered to employees in employee benefit plans) | |
| 2020-09-09 | SC 13G/A (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-09-03 | 8-K (Current report) | |
| 2020-09-03 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-08-17 | 424B4 (Prospectus [Rule 424(b)(4)]) | |
| 2020-08-14 | EFFECT (Notice of Effectiveness) | |
| 2020-08-12 | UPLOAD (SEC-generated letter) | |
| 2020-08-12 | CORRESP (Correspondence) | |
| 2020-08-11 | D (Notice of Exempt Offering of Securities) | |
| 2020-08-10 | SC 13G (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-08-10 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-08-07 | S-3 (Registration statement under Securities Act of 1933) | |
| 2020-08-03 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-03 | 8-K (Current report) | |
| 2020-07-31 | EFFECT (Notice of Effectiveness) | |
| 2020-07-30 | UPLOAD (SEC-generated letter) | |
Cyclerion Therapeutics, Inc (CYCN) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Cyclerion Therapeutics, Inc (CYCN). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1505%
Institutional Ownership: 7216%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-02-21 | William Huyett | Chief Financial Officer | Sell | 3,559.00 | 5.12 | 18,222.08 | 71,417.00 | |
| 2019-12-30 | Mark G Currie | President | Sell | 25,000.00 | 2.48 | 62,000.00 | 271,755.00 | |
| 2019-12-27 | Mark G Currie | President | Sell | 25,000.00 | 2.55 | 63,750.00 | 296,755.00 | |
| 2019-11-15 | Andreas Busch | Chief Innovation Officer | Buy | 125,000.00 | 1.82 | 227,500.00 | 125,000.00 | |
| 2019-11-08 | William Huyett | Chief Financial Officer | Sell | 3,922.00 | 2.05 | 8,040.10 | 74,976.00 | |
| 2019-07-10 | Peter M Hecht | Chief Executive Officer | Buy | 2,000.00 | 6.04 | 12,080.00 | 225,192.00 | |
| 2019-04-08 | AMY W SCHULMAN | Director | Buy | 21,635.00 | 16.00 | 346,160.00 | 21,635.00 | |
| 2019-04-08 | TERRANCE MCGUIRE | Director | Buy | 21,635.00 | 16.00 | 346,160.00 | 21,635.00 | |
| 2019-04-08 | AMY W SCHULMAN | Director | Buy | 604,482.00 | 16.00 | 9,671,712.00 | 604,482.00 | |
| 2019-04-08 | TERRANCE MCGUIRE | Director | Buy | 604,482.00 | 16.00 | 9,671,712.00 | 604,482.00 | |
| 2019-04-02 | Mark G Currie | President | Buy | 270,107.00 | 14.81 | 4,000,284.67 | 321,755.00 | |
| 2019-04-01 | Marsha Fanucci | Director | Buy | 13,671.00 | 13,671.00 | | ||
| 2019-04-01 | TERRANCE MCGUIRE | Director | Buy | 162.00 | 162.00 | | ||
| 2019-04-01 | Marsha Fanucci | Director | Buy | 3,279.00 | 16,950.00 | | ||
| 2019-04-01 | Peter M Hecht | Chief Executive Officer | Buy | 223,192.00 | 223,192.00 | | ||
| 2019-04-01 | GEORGE H CONRADES | Director | Buy | 2,421.00 | 2,421.00 | | ||
| 2019-04-01 | Kevin Churchwell | Director | Buy | 2,421.00 | 2,421.00 | | ||
| 2019-04-01 | Michael Mendelsohn | Director | Buy | 2,421.00 | 2,421.00 | | ||
| 2019-04-01 | Ole Isacson | Director | Buy | 2,421.00 | 2,421.00 | | ||
| 2019-04-01 | Stephanie Lovell | Director | Buy | 2,421.00 | 2,421.00 | |